Login/Sign Up
MRP ₹9900
(Inclusive of all Taxes)
₹1485.0 Cashback (15%)
Provide Delivery Location
Online payment accepted
Whats That
About Etibo 250 mg Tablet
Etibo 250 mg Tablet is an anti-cancer medicine used in the treatment of Breast cancer. The abnormal growth of cancer (malignant) cells in the breast is known as breast cancer. Etibo 250 mg Tablet is used in combination with capecitabine for treating patients with HER2-positive advanced or metastatic breast cancer who have received prior treatment, including anthracycline, taxane, and trastuzumab. This medicine is also used in combination with letrozole for the treatment of hormone receptor-positive metastatic breast cancer in patients with HER2-positive (human epidermal growth factor receptor 2) for whom hormonal therapy is indicated.
Etibo 250 mg Tablet contains Lapatinib as an active ingredient which belongs to the class of kinase inhibitors. It works by inhibiting the excess production of a human epidermal growth factor receptor 2 (HER2) protein in the mammalian cells. This causes inhibition of the cancer cell growth and, finally, initiation of apoptosis.
Etibo 250 mg Tablet may cause certain side effects such as diarrhea, fatigue, nausea, rash, indigestion, loss of appetite, headache, vomiting, weakness, mouth sores, hair loss, dry skin, myalgia, and allergic reactions. Most of these side effects do not require medical attention and gradually resolve over time. However, if the side effects persist, please consult your doctor. Etibo 250 mg Tablet should be taken as advised by your doctor. Take the medicine around the same time daily. Do not skip any dose; if you forget any dose, try to take it as soon as you remember unless it is time for your next dose. Do not double the dose.
Etibo 250 mg Tablet should be avoided if you are allergic to it or any other components of this medicine. Before starting the treatment, let your doctor know about your complete medical history and medication history, including vitamin and herbal supplements. Inform your doctor if you have any cardiovascular conditions or liver/kidney disease before taking Etibo 250 mg Tablet . Etibo 250 mg Tablet is known to cause embryo-fetal toxicity. Hence, if you are pregnant or breastfeeding, inform your doctor beforehand.
Uses of Etibo 250 mg Tablet
Directions for Use
Medicinal Benefits
Etibo 250 mg Tablet contains Lapatinib as an active ingredient, which is used in combination with capecitabine for treating patients with HER2-positive advanced or metastatic breast cancer who have received prior treatment. This medicine works by inhibiting the excess production of a human epidermal growth factor receptor 2 (HER2) protein in the mammalian cells. This causes inhibition of the cancer cell growth and, finally, initiation of apoptosis.
Storage
Drug Warnings
Etibo 250 mg Tablet should be avoided if you are allergic to it or any other components of this medicine. Inform your doctor if you have any cardiovascular conditions or liver/kidney disease, as it can cause adverse effects. Etibo 250 mg Tablet may cause left ventricular ejection fraction, prolonged QT interval, hepatotoxicity, interstitial lung disease, pneumonitis, severe diarrhoea, and hypersensitivity reactions during the treatment. Hence, careful observation should be performed for any reactions in the patient. If any changes or hypersensitivity reactions occur, treatment should be discontinued. Etibo 250 mg Tablet is known to cause embryo-fetal toxicity. Hence, if you are pregnant or planning to become pregnant, inform your doctor beforehand. Breastfeeding should be discontinued in nursing mothers during the treatment. Etibo 250 mg Tablet should be given to children only if prescribed by the paediatrician. Etibo 250 mg Tablet is not recommended for use in children as the safety and efficacy are not established. Avoid alcohol consumption and smoking, as it can lead to serious adverse effects.
Drug-Drug Interactions
Login/Sign Up
Drug-Food Interactions
Login/Sign Up
Diet & Lifestyle Advise
Side Effects of Etibo 250 mg Tablet
Habit Forming
Therapeutic Class
Product Substitutes
We provide you with authentic, trustworthy and relevant information
Drug-Diseases Interactions
Login/Sign Up
Etibo 250 mg Tablet contains Lapatinib, which works by inhibiting the excess production of a protein called human epidermal growth factor receptor 2 (HER2) in mammalian cells. This causes inhibition of the cancer cell growth.
Inform your doctor whether you have received any other breast cancer treatment. Etibo 250 mg Tablet may cause left ventricular ejection fraction, hypersensitivity reactions, hepatotoxicity, severe diarrhea, and embryo-fetal toxicity during the treatment. Hence, inform your oncologist if you have any cardiovascular conditions, liver/kidney disease, are pregnant, are planning to become pregnant, or are breastfeeding before taking Etibo 250 mg Tablet .
Hepatotoxicity (liver toxicity) has been reported in clinical studies and postmarketing experience with Etibo 250 mg Tablet . Hepatotoxicity can be fatal, and deaths have been reported. The cause of death is unknown. If you have upper stomach pain, itching, dark urine, clay-coloured faeces, or jaundice (yellowing of the skin or eyes), inform your doctor immediately.
Drug-Drug Interactions Checker List
Special Advise
Disease/Condition Glossary
Breast Cancer: Breast cancer is a type of cancer with abnormal growth in the cells of the breast. There are different kinds of breast cancer, such as cancer occurring in lobules (glands that produce milk), ducts of the breast (the pathway that brings milk from glands to the nipple), and in the fatty tissue or the fibrous connective tissue within the breast. Symptoms of breast cancer include a lump in the breast, breast pain, redness, swelling, nipple discharge other than breast milk, bloody discharge, a lump or swelling under the arm, unexplained change in shape, size or appearance of the breast, peeling, flaking or scaling of the skin.
Have a query?
Buy best Neoplastic Disorders products by
Intas Pharmaceuticals Ltd
Natco Pharma Ltd
Dr Reddy's Laboratories Ltd
Cipla Ltd
Celon Laboratories Pvt Ltd
Sun Pharmaceutical Industries Ltd
Alkem Laboratories Ltd
United Biotech Pvt Ltd
Zydus Cadila
Zydus Healthcare Ltd
Neon Laboratories Ltd
Glenmark Pharmaceuticals Ltd
Mylan Pharmaceuticals Pvt Ltd
BDR Pharmaceuticals Internationals Pvt Ltd
Emcure Pharmaceuticals Ltd
Adley Formulations
Samarth Life Sciences Pvt Ltd
Hetero Drugs Ltd
Torrent Pharmaceuticals Ltd
Fresenius Kabi India Pvt Ltd
Pfizer Ltd
Admac Lifesciences(Oncology)
Adley Pharmaceuticals Ltd
Novartis India Ltd
Halsted Pharma Pvt Ltd
Getwell Life Sciences India Pvt Ltd
Lupin Ltd
Cadila Healthcare Ltd
Hetero Healthcare Pvt Ltd
GLS Pharma Ltd
Reliance Formulation Pvt Ltd
Abbott India Ltd
Aimcad Biotech Pvt Ltd
Astra Zeneca Pharma India Ltd
Therdose Pharma Pvt Ltd
Axiommax Oncology Pvt Ltd
Biochem Pharmaceutical Industries Ltd
Khandelwal Laboratories Pvt Ltd
Msn Laboratories Pvt Ltd
Aureate Healthcare
Caitlin Oncology
Dabur India Ltd
Zee Laboratories Ltd
Sarabhai Chemicals (India) Pvt Ltd
Wembrace Biopharma Pvt Ltd
Delarc Pharmaceuticals Pvt Ltd
Medaegis Biotek Pvt Ltd
Panacea Biotec Ltd
RPG Life Sciences Ltd
Shilpa Medicare Ltd
Getwell Oncology Pvt Ltd
Ipca Laboratories Ltd
Miracalus Pharma Pvt Ltd
Biocon Ltd
Cadila Pharmaceuticals Ltd
Eli Lilly and Company (India) Pvt Ltd
Ferring Pharmaceuticals Pvt Ltd
Fresenius Kabi Oncology Ltd
Getwell Pharmaceutical Pvt Ltd
Maximal Healthcare Pvt Ltd
Boehringer Ingelheim India Pvt Ltd
Del Trade International Pvt Ltd
Sayre Therapeutics Pvt Ltd
Akumentis Healthcare Ltd
Corona Remedies Pvt Ltd
Eisai Pharmaceuticals India Pvt Ltd
GlaxoSmithKline Pharmaceuticals Ltd
Hilfen Pharmaceuticals Pvt Ltd
Johnson & Johnson Pvt Ltd
Mankind Pharma Pvt Ltd
Merck Ltd
Oncostar Pharma Pvt Ltd
Rhone Poulenc Rorer India Pvt Ltd
Vhb Life Sciences Inc
Zuventus Healthcare Ltd
Admac Pharma Ltd
Adonis Laboratories Pvt Ltd
Alniche Life Sciences Pvt Ltd
BPRL Pvt Ltd
Caitlin Life Care
Dr Care
German Remedies Ltd
Janssen Pharmaceuticals Pvt Ltd
MEDICAMEN BIOTECH LTD
Maxis Healthcare (I) Pvt Ltd
Pharm Products Pvt Ltd
Accord Life Spec Pvt Ltd
Amps Biotech Biotech Pvt Ltd
Aphia Healthcare
Astellas Pharma India Pvt Ltd
Bangalore Pharmaceutical and Research Laboratory Pvt Ltd (BPRL)
Bharat Serums and Vaccines Ltd
Cellgen Biopharma
Cosmic Life Sciences
Daris Biocare
East West Pharma India Pvt Ltd
Hillrock Biotech Pvt Ltd
Lucien Life Sciences
Maneesh Pharmaceuticals Ltd
Medilief Bioscience Pvt Ltd
Alcohol
Unsafe
Alcohol intake might increase the risk of worsening your condition. Hence, avoid alcohol consumption till your condition improves.
Pregnancy
Unsafe
Etibo 250 mg Tablet is not recommended for use in pregnancy as it may harm your foetus. Hence, if you are pregnant or planning pregnancy, inform your doctor before taking Etibo 250 mg Tablet . Use reliable methods of birth control while on treatment with Etibo 250 mg Tablet .
Breast Feeding
Unsafe
Avoid nursing your child while on treatment with Etibo 250 mg Tablet as it can cause serious side effects to the newborn baby.
Driving
Consult your doctor
It is unknown whether Etibo 250 mg Tablet will affect your mental ability to drive or operate machines. Hence, consult your doctor for information regarding this.
Liver
Caution
Inform your doctor if you have any pre-existing liver disease. Your doctor may adjust the dose of the medicine based on the condition. Etibo 250 mg Tablet is known to cause hepatotoxicity in some patients. If you notice any reactions such as itching, yellowing of the skin or eyes, dark urine, abdominal pain, unusual bleeding, or pale or dark stools, discontinue the treatment and inform your doctor immediately.
Kidney
Caution
Limited data are available on the effect of Etibo 250 mg Tablet in kidney-impaired patients. Hence, if you have a pre-existing or a history of kidney disease, inform your doctor.
Children
Unsafe
Etibo 250 mg Tablet is not recommended for use in children as the safety and efficacy are not established.